Say good­bye to Val­lon as a low-pro­file NKT cell start­up steps in­to its bat­tered shoes on Nas­daq

Eight months af­ter Val­lon Phar­ma­ceu­ti­cals’ late-stage shot at R&D glo­ry end­ed in a short, sharp im­plo­sion with the fail­ure of a Phase III study for its lead AD­HD drug, the tiny biotech will hand over its pub­lic list­ing in a re­verse merg­er that will shove a low-pro­file NKT cell play­er in­to the pub­lic are­na.

Val­lon $VLON will now dis­ap­pear un­der the storm-tossed seas of Nas­daq, as GRI Bio in San Diego tries its hand at drug de­vel­op­ment as a pub­lic com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.